Compare Incyte Corporation (INCY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vipshop Holdings Ltd - ADR — how do they compare? Incyte Corporation trades at $120.94 (market cap $24.54B), while Vipshop Holdings Ltd - ADR trades at $14.43 (market cap $7.20B). The key difference: Incyte Corporation is far larger — about 3.4× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VIPS | |
|---|---|---|
Market Cap | $24.54B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $20.68 |
52-Week Low | $81.61 | $12.92 |
Enterprise Value | $20.04B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
VIPS stock trades at $14.31, down 7.14% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.68, meeting expectations, and maintains strong profitability with a net income margin of 7.07%. Recent news highlights growth initiatives, including an outlet strategy to boost performance amid industry challenges.
The outlook for VIPS is cautiously optimistic, supported by low valuation multiples like a P/E of 6.79 and a buy consensus from 53.57% of analysts. Risks include revenue stagnation and macroeconomic pressures, but the stock's discounted valuation may offer upside if growth resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
